Home
News
Latest News
People Moves
Business Briefs
Newsletters
Features
Features
Reprints
Surveys
Editorial Calendar
Web Exclusives
Issue Archive
Events
MM&M Awards 2012
txt4pharma
MM&M Virtual Summit
Webcasts
Leadership Exchanges
Whitepapers
Directories
Creative Portfolio
Mobile Guide
Interactive Guide
Pharmaceutical Marketers Directory
MM&M Service Directory
Agency Gallery
Direct Marketing Showcase
Medical Education Review
Sales Force Listings
Jobs
About Us
Subscriber Services
Contact Us
Media Information
Editorial Advisory Board
Drug Info
New Drug Dossier
Drug Database
Subscribe
Order Now
Subscriber Services
Newsletters
RSS
|
Login
|
Register
FDA
PhRMA's Washington wish list
Matthew Arnold
May 21, 2012
PhRMA presented Washington with its legislative wish list - and a warning that plenty of other countries are trying to woo the industry away from the US.
RX-to-OTC proposal gets mixed reviews
Deborah Weinstein
May 14, 2012
Industry and physician groups expressed wary support for the FDA's "new paradigm" drug proposal, which would create a nonprescription "Behind the Counter" class of drugs available through pharmacists.
Humira on solid ground, analysts say, despite vote on Pfizer hopeful
Deborah Weinstein
May 10, 2012
The general consensus surrounding the FDA advisory panel's 8-2 vote in favor of Pfizer's rheumatoid arthritis hopeful tofacitinib yesterday was that Abbott's Humira doesn't have to watch its back.
Report: FDA hitting PDUFA targets, critics be darned
Deborah Weinstein
May 03, 2012
The latest word from the Government Accountability Office: back off the FDA. The government research agency's newest report says the FDA is plowing through new- and biologics- drug applications at a speedy pace.
Social media an outcomes listening post for pharma
Marc Iskowitz
March 27, 2012
FDA issues may deter drugmakers from engaging in social media, but that's no excuse to ignore what audiences are saying on these platforms, say pharma and device firms.
Shire exits Fabry's market, citing costs as FDA weighs more research
Deborah Weinstein
March 15, 2012
Shire has pulled its drug, Replagal, from FDA review. The company was set to go before the agency next month, but preliminary talks indicated the FDA was going to require more testing.
FDA's 45-day TV ad review "shot clock" in guidance
Matthew Arnold
March 12, 2012
TV ads for most prescription drugs must be submitted to FDA for pre-clearance 45 days before the manufacturer intends to air them, according to an FDA draft guidance in tomorrow's Federal Register.
An FDA denial, but not the last word on Merck combo lipid drug
Marc Iskowitz
March 06, 2012
An experimental lipid-lowering combo drug developed by Merck hit a snag, but its real test is yet to come, says one analyst.
Med Ed Report briefs—March 2012
Marc Iskowitz
March 01, 2012
News on FDA, Med-IQ, the American Medical Student Association, Best Practices, the American College of Physicians and CECity
FDA study finds little harm in 'distracting visuals'
Matthew Arnold
March 01, 2012
An FDA study on the power of background visuals found no evidence that consumer understanding of risk info is affected by the "emotional (affective) tone of images."
As I See It: Global systems for quality and safety
Peter Pitts March 01, 2012
It's time for a regulatory Marshall plan to help build global systems for quality and safety
Sens. Klobuchar, Collins push drug-shortage bill
James G. Dickinson
March 01, 2012
U.S. senators Amy Klobuchar and Susan Collins are trying to quickly pass a bill addressing the growing drug shortage problem
User-fee inaction could cause logjam
James G. Dickinson
March 01, 2012
Congressional inaction could lead to a huge new products-review backlog, according to FDA Matters editor Steven Grossman.
FDA to study "corrective" ads
Matthew Arnold
February 29, 2012
The FDA will study the impact of corrective advertising on consumer misperceptions of drug safety and efficacy.
Company news: Biogen-Idec, Bristol-Myers Squibb and Pfizer
February 29, 2012
Biogen-Idec is submitting its multiple sclerosis drug BG-12 for formal FDA scrutiny.
Industry group releases digital best practices
Matthew Arnold
February 06, 2012
Weary of FDA foot-dragging on digital and social media guidance for pharmas, a group of 60-some industry digerati have put together guidelines of their own.
FDA study casts doubt on danger of "distracting visuals"
Matthew Arnold
January 31, 2012
An FDA study looking at the power of background visuals to distract viewers from the often-ominous risk info read in the "major statement" section of TV drug ads found no evidence that consumer understanding of risk info is affected by the "emotional (affective) tone of images.
FDA gives guidance on brand, generic names in ads
Matthew Arnold
January 26, 2012
The FDA issued guidance clarifying narrow questions of scientific or generic name placement in ads and labeling in different media, including electronic media.
Tysabri gets boost from label change, new diagnostic
Deborah Weinstein
, Marc Iskowitz January 23, 2012
Biogen Idec and Elan, which market Tysabri for multiple sclerosis, won approval to add new safety information to the drug's label that could boost sales by helping doctors avoid a serious adverse event.
Company news: Gilead, Pfizer and Wolters Kluwer
December 29, 2011
Two potential blockbusters in the pharma pipeline took another step toward reaching market, as US regulatory authorities assigned PDUFA dates for Gilead Sciences' Quad pill and for Pfizer's tofacitinib.
DOJ hit pharmas for $2.2 billion in 2011 False Claims Act cases
Matthew Arnold
December 20, 2011
Pharmas shelled out $2.2 billion in False Claims Act fines and settlements with the Justice Department this year as the feds' healthcare fraud haul hit an all-time high.
How Genentech cut journal ads across all Avastin indications
Marc Iskowitz
December 05, 2011
Well before the FDA revoked Avastin's approval in breast cancer, Roche's Genentech unit deeply cut the professional media plan for the drug, the company said.
Since Vioxx scare, tough times for industry R&D, study finds
Matthew Arnold
December 01, 2011
A review of 450 New Molecular Entities spanning a decade and a half found two distinct eras of drug R&D - one of abundance and one of scarcity, hinging on the September, 2004 withdrawal of Merck's Vioxx.
Merck wraps up Vioxx litigation with feds, states: $1b in fines, new CIA
Matthew Arnold
November 22, 2011
Seven years after the biggest drug safety scandal since thalidomide was found to cause birth defects, Merck and the Justice Department announced a nearly $1 billion settlement of litigation over Vioxx, the Cox-2 pain drug found to cause strokes and heart attacks.
Par Pharma suit could set up off-label court showdown
Matthew Arnold
October 18, 2011
Par Pharmaceutical last week asked a federal court to tell the FDA to back off and allow the company to detail docs about using its Megace ES to treat AIDS-related wasting.
Company news: FDA, Ranbaxy, Daiichi Sankyo and ImpactRx
October 06, 2011
The FDA issued Driving Innovation, a blueprint for fostering American biomedical innovation, reiterating a prior commitment to reform regulation and announcing policies aimed at facilitating personalized medicine.
Say so long to DDMAC as FDA's OPDP levels up
Matthew Arnold
September 19, 2011
The FDA gave its Office of Medical Policy a long-awaited org chart upgrade, making it a "super office" and giving the department formerly known as the Division of Drug Marketing, Advertising and Communication, or DDMAC, a new acronym: OPDP.
FDA, industry agree on PDUFA deal to speed NME reviews
Matthew Arnold
September 01, 2011
The FDA and the biopharma industry have agreed in principle on a revamp of the Prescription Drug User Fee Act (PDUFA), by which pharmas provide nearly two-thirds of what the agency spends on drug reviews.
Pfizer's Xalkori and Abbott test show promise in personalized medicine, companion diagnostics
Matthew Arnold
August 30, 2011
The FDA's approval of Pfizer's Xalkori (crizotinib) represents a leap forward for both personalized medicine and Pfizer's R&D turnaround, but its commercial success hinges on a pricey diagnostic array by Abbott's Vysis.
FDA to IOM: More work? No thanks
Matthew Arnold
August 11, 2011
The FDA is moving cautiously on a call by the Institute of Medicine to scrap the approvals process for many medical devices.
Video Exclusive
Web Exclusives
Five industry experts advise specialty pharma company on digital strategy
April 20, 2012
Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.
MM&M Awards 2011 HIghlights
The Best MM&M Awards Ever!
MAHF Ceremony 2012
Photos from the Medical Advertising Hall of Fame Awards ceremony
Most Popular
Most Emailed
Most Recent
Goodbye Plavix, hello competition
Sales forces shrank in 2011, but not everywhere
Wolters Kluwer deals health analytics unit to private equity firm
Pharmas are from Mars, Payers are from Venus
Study: Young Latinas are key decision makers, prefer English
Coach vs. cancer in BMS-backed awareness effort
Indian conglomerate buys Manhattan Research parent for $635m
No-see docs are know-nothings when it comes to new drug info, study suggests
How CDC's hep.-C testing advice benefits drugmakers now
National plan seeks Alzheimer's treatment by 2025
Study: Young Latinas are key decision makers, prefer English
Wolters Kluwer deals health analytics unit to private equity firm
Pharmas are from Mars, Payers are from Venus
Indian conglomerate buys Manhattan Research parent for $635m
No-see docs are know-nothings when it comes to new drug info, study suggests
Goodbye Plavix, hello competition
Sales forces shrank in 2011, but not everywhere
Coach vs. cancer in BMS-backed awareness effort
National plan seeks Alzheimer's treatment by 2025
E-prescriptions boost adherence data
No-see docs are know-nothings when it comes to new drug info, study suggests
E-prescriptions boost adherence data
How CDC's hep.-C testing advice benefits drugmakers now
PhRMA's Washington wish list
Study: Young Latinas are key decision makers, prefer English
Pharmas are from Mars, Payers are from Venus
Goodbye Plavix, hello competition
Indian conglomerate buys Manhattan Research parent for $635m
Sales forces shrank in 2011, but not everywhere
National plan seeks Alzheimer's treatment by 2025
Popular Topics
Acquisition
Adherence
Agency
App
Celebrity
Clinical Trial
Co-Marketing
Conflict Of Interest
Diabetes
Diagnostics
Digital
Direct To Consumer (DTC)
Disease Awareness
Downsize
Education & Awareness
FDA
Government
Guidance
Health Plans
HMOs
Hospitals
Insurers
Law
Marketing Research
Sales Force